Clinical trial data and FDA labeling information indicate that gastrointestinal effects are dose-dependent and typically most pronounced during initial treatment or dose escalation
The most common adverse reactions for Wegovy (incidence 5%) in adults or pediatric patients aged 12 years and older are: nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and hair loss
Key Takeaway: Semaglutide helps reduce the amount of fuel you take in, while NAD helps your cells burn that fuel more effectively
[22] Regular follow-up with your prescribing clinician is essential to monitor treatment response, adjust dosing, and address any emerging side effects
Delayed gastric emptying leaves food and liquid in the stomach longer, increasing stretch and chemical stimulus to visceral afferents that communicate with the brainstem nausea centers